Stay updated with breaking news from இருதய மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Therapeutic Proteins Market Is Being Driven By Advanced Drug Development Technologies einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Global Radiopharmaceuticals Market Trends, Strategies, And O... menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
HP (High Potency) APIs Global Market Report 2021: COVID-19 Growth And Change To 2030 The Business Research Company’s HP (High Potency) APIs Global Market Report 2021: COVID-19 Growth And Change To 2030 LONDON, GREATER LONDON, UK, July 29, 2021 /EINPresswire.com/ The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the high potency APIs market. This rising incidence of cancer is resulting in increasing R&D for anticancer drugs, which in turn is propelling the demand for high potency APIs market. According to the World Health Organization’s International Agency for Research on Cancer (IARC) report published in 2018, the cancer burden is expected to increase 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market. ....
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland - June 2 , 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y 12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, e ....